Jpmorgan Chase & CO Roivant Sciences Ltd. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 822,582 shares of ROIV stock, worth $9.87 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
822,582
Previous 788,129
4.37%
Holding current value
$9.87 Million
Previous $8.33 Million
13.95%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ROIV
# of Institutions
310Shares Held
507MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$791 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$790 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$649 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$500 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$424 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.45B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...